Enzomend-D Tablet is a combination pharmaceutical formulation containing Trypsin (48 mg), Bromelain (90 mg), Rutoside (100 mg), and Diclofenac (50 mg), designed to provide effective anti-inflammatory, analgesic, and fibrinolytic effects. Trypsin and Bromelain are proteolytic enzymes that facilitate the breakdown of proteins, thereby reducing inflammation and edema by promoting the absorption of inflammatory exudates. Rutoside, a bioflavonoid, enhances capillary strength and reduces capillary permeability, contributing to the reduction of swelling and bruising. Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), exerts potent analgesic and anti-inflammatory actions by inhibiting cyclooxygenase enzymes, thereby decreasing the synthesis of prostaglandins responsible for pain and inflammation. The synergistic action of these components makes Enzomend-D effective in managing acute musculoskeletal conditions such as sprains, strains, contusions, and postoperative inflammation. It is indicated for symptomatic relief of pain and inflammation associated with trauma, sports injuries, and postoperative recovery. Enzomend-D should be used under medical supervision, with caution advised in patients with hypersensitivity to NSAIDs, bleeding disorders, or gastrointestinal ulcers. The combination therapy aims to accelerate recovery by reducing pain, swelling, and tissue damage, improving patient mobility and quality of life.